Radiomic Features Predict Ki-67 Expression Level and Survival in Lower Grade Gliomas
Overview
Affiliations
To investigate the radiomic features associated with Ki-67 expression in lower grade gliomas and assess the prognostic values of these features. Patients with lower grade gliomas (n = 117) were randomly assigned into the training (n = 78) and validation (n = 39) sets. A total of 431 radiological features were extracted from each patient. Differential radiological features between the low and high Ki-67 expression groups were screened by significance analysis of microarrays. Then, generalized linear analysis was performed to select features that could predict the Ki-67 expression level. Predictive efficiencies were further evaluated in the validation set. Cox regression analysis was performed to investigate the prognostic values of Ki-67 expression level and Ki-67-related radiological features. A group of nine radiological features were screened for prediction of Ki-67 expression status; these achieved accuracies of 83.3% and 88.6% (areas under the curves, 0.91 and 0.93) in the training and validation sets, respectively. Of these features, only spherical disproportion (SD) was found to be a prognostic factor. Patients in the high SD group exhibited worse outcomes in the whole cohort (overall survival, p < 0.0001; progression-free survival, p < 0.0001). Ki-67 expression level and SD were independent prognostic factors in the multivariate Cox regression analysis. This study identified a radiomic signature for prediction of Ki-67 expression level as well as a prognostic radiological feature in patients with lower grade gliomas.
Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.
Zhao X, Zhang Y, Wang Y, Ren X, Zhang X, Wan H J Neurooncol. 2025; .
PMID: 39827421 DOI: 10.1007/s11060-024-04929-3.
Liang H, Wang Z, Li Y, Ren A, Chen Z, Wang X BMC Med Imaging. 2024; 24(1):244.
PMID: 39285364 PMC: 11403938. DOI: 10.1186/s12880-024-01414-1.
Enhancing neuro-oncology care through equity-driven applications of artificial intelligence.
Mehari M, Sibih Y, Dada A, Chang S, Wen P, Molinaro A Neuro Oncol. 2024; 26(11):1951-1963.
PMID: 39159285 PMC: 11534320. DOI: 10.1093/neuonc/noae127.
Artificial intelligence-based MRI radiomics and radiogenomics in glioma.
Fan H, Luo Y, Gu F, Tian B, Xiong Y, Wu G Cancer Imaging. 2024; 24(1):36.
PMID: 38486342 PMC: 10938723. DOI: 10.1186/s40644-024-00682-y.
Lan L, Feng K, Wu Y, Zhang W, Wei L, Che H Phenomics. 2024; 3(6):597-612.
PMID: 38223684 PMC: 10781914. DOI: 10.1007/s43657-023-00128-8.